for an array of medical conditions. With what many are
calling a race to the bottom for the recreational retail industry, the real value (and money to be made) just may be on the medical side as well as the CannaInvestor hypothesis that edibles and beverages will command premium pricing and margins compared to dry flower.
One cannot help but put for the supposition that perhaps a key driver behind the lack of effective synthetic THC drugs when compared to the natural whole plant may be rooted, at least in part, in the fact that the synthetic variants are devoid of terpenes as well as other cannabinoids. For those of you thinking outside the box … could this mean adding the right terpenes (and amounts) to a synthetic THC such as Marinol could
elevate their effectiveness?
For those of you particularly interested in Terpenes, I would suggest you look no further than Terpenes & Testing Magazine’s website – complete with webinars, educational material, and a bountiful resource library.
I was fortunate enough to recently have the opportunity to discuss this further with none other than Ian Morton and Dr. Tariq Akhtar of Molecular Science Corp and that brief Q & A follows:
180